This page will host Events plug-in for all Clarion and trade events.

Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares U.S. Pharmaceutical ETF (NY:IHE)

101.11 +0.49 (+0.49%)
Streaming Delayed Price Updated: 3:56 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares U.S. Pharmaceutical ETF

< Previous 1 2 3 Next >
News headline image
XLV vs. IHE: Which Healthcare ETF Is the Better Buy? ↗
IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF? ↗
IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower cost. 
Via The Motley Fool
Topics ETFs
News headline image
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗
BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers. 
Via The Motley Fool
Topics ETFs
KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show? ↗
Via Stocktwits
Why Did NRXP Stock Surge 21% Pre-Market Today? ↗
Via Stocktwits
White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗
Via Stocktwits
News headline image
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? ↗
IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance? 
Via The Motley Fool
Topics ETFs
News headline image
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? ↗
IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles. 
Via The Motley Fool
Topics ETFs
News headline image
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗
Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years. 
Via The Motley Fool
Topics ETFs
News headline image
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors? ↗
Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗
Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability. 
Via The Motley Fool
Topics ETFs
News headline image
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns ↗
One fund channels profits to breast cancer research, while the other focuses on established drugmakers. See how their strategies shape risk and sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game. ↗
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report ↗
The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary. 
Via Stocktwits
News headline image
TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint ↗
The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint. 
Via Stocktwits
Topics Workforce
News headline image
FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗
Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments. 
Via Stocktwits
Topics ETFs Government
News headline image
Why Did IINN Stock Surge 28% In Pre-Market Today? ↗
The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members. 
Via Stocktwits
News headline image
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗
The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month. 
Via Stocktwits
Topics Intellectual Property
News headline image
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗
Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data. 
Via Stocktwits
News headline image
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗
The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days. 
Via Stocktwits
Topics World Trade
News headline image
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗
A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize. 
Via Benzinga
Topics ETFs
News headline image
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them." 
Via Benzinga
News headline image
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
News headline image
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
News headline image
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers. 
Via Benzinga
Topics Government World Trade
News headline image
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices. 
Via Benzinga
News headline image
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation. 
Via Benzinga
News headline image
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' ↗
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken... 
Via Benzinga
News headline image
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. 
Via Benzinga
Topics Artificial Intelligence ETFs
News headline image
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.